Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Abstract Background With the revolutionary progress of immune checkpoint inhibitors (ICIs) achieved in non-small cell lung cancers (NSCLC), identifying patients benefiting from ICIs becomes critical and urgent. The associations of genomic alterations in protein tyrosine phosphatase receptor-type (PT...

Full description

Bibliographic Details
Main Authors: Yiting Sun, Jianchun Duan, Wenfeng Fang, Zhijie Wang, Xinyang Du, Xin Wang, Chengcheng Li, Shangli Cai, Jie Zhao, Sini Li, Li Zhang, Hua Bai, Jie Wang
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Medicine
Subjects:
Biomarker
PTPRD
Immune checkpoint inhibitor
Non-small cell lung cancer
Online Access:https://doi.org/10.1186/s12916-021-02075-5

Internet

https://doi.org/10.1186/s12916-021-02075-5

Similar Items